Clinical Trial Update: An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study. [Phase 3]

View source ↗

Summary

An open-label extension study is evaluating the long-term safety and efficacy of once-daily Mexiletine prolonged-release in patients with myotonic dystrophy typ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myotonic Dystrophy Type

Drugs mentioned

• Mexiletine PR (Mexiletine)

Snippet

Sponsor: Lupin Ltd. | Conditions: Myotonic Dystrophy | Phase 3 | Status: ENROLLING_BY_INVITATION